[1] Bhat M, Ghali P, Deschenes M, et al. Prevention and management of chronic hepatitis B. Int J Prev Med, 2014,Suppl 3:S200-7.
[2] Qiu B, Jiang, W,Olyaee M, et al. Advances in the genome-wide association study of chronic hepatitis B susceptibility in Asian population. Eur J Med Res, 2017,22: 55.
[3] Gill US, Pallett LJ, Kennedy PTF, et al. Liver sampling: a vital window into HBV pathogenesis on the path to functional cure. Gut, 2018, 67: 767-775.
[4] Atan O, Aksu G, Ozgenc F, et al. Determination of intracellular Th1/Th2 type cytokines in lymphocytes of chronic hepatitis B patients treated with interferon-alpha. Turk J Gastroenterol, 2010,21: 401-410.
[5] Li MH, Zhang L, Zhang D, et al. Plasmacytoid dendritic cell function and cytokine network profiles in patients with acute or chronic hepatitis B virus infection. Chin Med J (Engl), 2018,131: 43-49.
[6] Li MH, Zhang D, Zhang L, et al. Ratios of T-helper 2 cells to T-helper 1 cells and cytokine levels in patients with hepatitis B. Chin Med J (Engl), 2017,130: 1810-1815.
[7] Wang Y, Yu W, Shen C, et al. Predictive value of serum IFN-gamma inducible protein-10 and IFN-gamma/IL-4 ratio for liver fibrosis progression in CHB patients. Sci Rep, 2017,7:40404. |
